Share this post on:

Product Name :
Brimapitide

Search keywords :
D-JNKI-1

drugId :
null

Target Vo:
c-Jun N-terminal kinase 1

Target Vo Short Name :
JNK1

Moa_Name:
c-Jun N-terminal kinase 1 inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Xigen Sa

Active Company_Name :

Active Indication_Name:

In Active Indication_Name:
Cataract

Termination Status :
Phase 3 Clinical

China Termination Status :

Highest Status:
Discontinued

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
IL-6 Antibody
Caspase-1 p20 Antibody
PRDX3 Antibody (YA909): PRDX3 Antibody (YA909) is an unconjugated, approximately 28 kDa, human-derived, anti-PRDX3 (YA909) monoclonal antibody. PRDX3 Antibody (YA909) can be used for: WB, IF-Cell, IHC-P, FC, IP expriments in human background without labeling.

Share this post on:

Author: Interleukin Related